<DOC>
	<DOCNO>NCT02246894</DOCNO>
	<brief_summary>The main objective study : - ass Optivate速 consumption ( IU/kg consume per month prophylactic on-demand therapy dose bleed ) . - assess clinical outcome treat bleed Optivate速 . - evaluate Optivate速 term clinical tolerance safety child age 6 year . . - ass FVIII inhibitor development study .</brief_summary>
	<brief_title>A Study Investigate Safety Efficacy Optivate速 Children Under 6 Years Age With Haemophilia A .</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Children age 6 year diagnosis severe Haemophilia A . Subjects require FVIII therapy demonstrate inhibitor FVIII . Children history inhibitor FVIII clinically significant renal liver disease eligible participate study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>